Q-Sera’s technology is based upon research emanating from the University of Queensland and is patent protected.
Intellectual Property
Family 1 Priority Date Sept 2010
'Serum Preparation'
PCTAU2011/001221
This patent covers all prothrombin activators from snake venom including naturally occurring and recombinant versions in blood collection tubes for the production of serum for biochemical analysis.
May 2020: Patent granted or allowed in US, EU, Japan, China, Canada, Mexico, Russia, South Korea, South Africa and Australia.
Patent pending in India, Israel and Brazil.
Family 2 Priority Date Oct 2014
'Improved Clotting Composition'
PCTAU2015/000629
Covers formulations to enhance the temperature and irradiation stability of snake venom prothrombin activators in blood collection tubes.
May 2020: Patent allowed in US and Japan.
Patent pending in EU, China, Canada, Australia and South Africa